Artificial Pancreas - Adolescent Physiology & Psychology Longitudinal Evaluation

NCT ID: NCT04510506

Last Updated: 2025-12-10

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 42 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2020-11-19
• Study Completion Date: 2025-10-24

Brief Summary

This study designed to assess changes in control of Type 1 Diabetes in pubertal adolescents over a two year period. There are two arms/substudies, the first being a longitudinal randomized controlled trial and the second an observational study.

Detailed Description

The investigators will recruit adolescents with type 1 diabetes age 11-<13 years and one parent to participate in this 24-month study. While this is admittedly a long enrollment time, study commitments following enrollment will be limited to three in-person or video visits at yearly intervals and one virtual or in-person device training session to improve adherence. Participants must be pubertal, as puberty appears to contribute significantly to the insulin resistance that is likely related to worsened blood glucose control. Pubertal assessments will occur at yearly intervals.

The first of the two arms/substudies ("Randomized" substudy) is a longitudinal randomized controlled trial for which participants will be randomized to either continue their current diabetes therapy (with the addition of use of a Dexcom CGM, forming the "Usual Care+CGM" Control Group; this includes both adolescents using non-automated insulin delivery (AID) insulin pumps or multiple daily injections [MDI]). The Experimental Group will use an AP system (Tandem's Control-IQ system) during the two-year duration of the study. The primary outcome of the Randomized substudy will be HbA1c between intervention groups at the 24-month visit.

The second arm/substudy ("Triple Label Surveillance" substudy) is an observational study. Both arms/substudies perform a "Triple Label" mixed meal study assessing glucose flux and insulin resistance that requires visits to the Clinical Research Unit. All participants will undergo a Triple-Labeled Glucose Assessment at months 0, 12 and 24. This assessment evaluates the degree of insulin resistance including in the hepatic and peripheral compartments. During Visit 2, all participants (for both the Triple Label sub-study and the Glycemia-Only sub-study) will complete multiple questionnaires assessing aspects of adolescent psychology and sociology. HbA1c will also be collected using a local lab. The primary outcome of the study overall (combined Triple Label Surveillance and Randomized substudies) is the change in insulin resistance between baseline and the 24-month visit.

CGM glucose data will be collected continuously via remote connection during the entire study. At months 6 and 18, participants will be contacted to obtain insulin management information and will have HbA1c measures assessed at a local clinic or laboratory. Additional scheduled phone calls will occur in the month before the in-person study visits to request HbA1c and confirm body composition/Triple-Labeled Glucose Assessment scheduling and discuss use of CGM and activity tracker. Participants will be contacted in the event of insufficient CGM or AP system use. For the Randomized substudy, in the Eperimental Group, insufficient use is defined as <60% AP use over a 3-month period. For the Control Group, less than 1 month of CGM data over a 3-month period is considered insufficient. If participants do not meet minimum use criteria in 2 successive periods, the participant will be discontinued from the study.

The investigators are targeting completion of 42 child/parent dyads combined between the Randomized substudy and the Triple Label Surveillance sub-study.

Conditions

Type 1 Diabetes

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: OTHER
• Blinding Strategy: NONE

Study Groups

Randomized substudy: Artificial Pancreas Therapy

Participants will use a study assigned Tandem t:slim X2 with Control-IQ Technology.for two years.

Group Type: EXPERIMENTAL

Artificial Pancreas (AP)

Intervention Type: DEVICE

The AP system used in this trial is the Tandem t:slim insulin pump with Control-IQ Technology. This system is FDA approved for use starting at age 14 years.

Randomized substudy: Usual Care + CGM

Participant will use their usual diabetes care along with a study CGM.

Group Type: NO_INTERVENTION

No interventions assigned to this group

Triple Label Surveillance substudy (observational arm)

Participants will remain on own baseline diabetes management (e.g. automated insulin delivery system, non-AID pump, MDI)

Group Type: NO_INTERVENTION

No interventions assigned to this group

Interventions

Artificial Pancreas (AP)

The AP system used in this trial is the Tandem t:slim insulin pump with Control-IQ Technology. This system is FDA approved for use starting at age 14 years.

Intervention Type: DEVICE

Eligibility Criteria

Inclusion Criteria

1. Age 11 to <13 years (at time of enrollment) with a parent/guardian (18+ yo) who is willing to participate with the child

2. At least Tanner 2 pubic hair (boys), Tanner 2 breast development (girls)

3. HbA1c <10 clinically obtained within the last 6 weeks; if the participant is unable to go to the laboratory or clinic because of stay-at-home orders, the entry hemoglobin A1c level can be assessed via outside laboratory (e.g. LabCorp), home HbA1c device, recent clinically-obtained HbA1c in past month..

4. Clinical diagnosis, based on investigator assessment, of type 1 diabetes for at least one year

5. Currently using insulin for at least six months

6. Both prior pump and MDI users will use insulin parameters such as carbohydrate ratio and correction factors consistently on their pump in order to dose insulin for meals or corrections

7. Access to internet and willingness to upload data during the study as needed

8. For females, not currently known to be pregnant or breastfeeding

9. If female and sexually active, must agree to use a form of contraception to prevent pregnancy while a participant in the study. A negative serum or urine pregnancy test will be required for all females of childbearing potential. Participants who become pregnant will be discontinued from the study. Also, participants who during the study develop and express the intention to become pregnant within the timespan of the study will be discontinued.

10. Willingness to suspend use of any personal CGM for the duration of the clinical trial once the study CGM is in use

11. Willingness to switch to lispro (Humalog) or aspart (Novolog) if not using already, and to use no other insulin besides lispro (Humalog) or aspart (Novolog) during the study, if randomized to the Control-IQ group.

12. Total daily insulin dose (TDD) at least 10 U/day and not more than 100 U/day

13. Willingness not to start any new non-insulin glucose-lowering agent during the course of the trial (including metformin, GLP-1 agonists, pramlintide, DPP-4 inhibitors, biguanides, sulfonylureas and naturaceuticals)

14. An understanding and willingness to follow the protocol and signed informed consent

15. Participants must have Internet access and a computer system that meets the requirements for uploading the study equipment.

16. Contact with primary diabetes physician to discuss study details and the participant's care, with study team continuing to feel that the participant is appropriate for study inclusion.

Exclusion Criteria

1. Hemoglobin A1c >10% clinically obtained within the past 6 weeks

2. A known medical condition that in the judgment of the investigator might interfere with the completion of the protocol such as the following examples:

1. Severe renal impairment, end-stage renal disease, or dialysis

2. Inpatient psychiatric treatment in the past six months

3. Presence of a known adrenal disorder

4. Abnormal liver function test results (Transaminase>2 times the upper limit of normal); testing required for subjects taking medications known to affect liver function or with diseases known to affect liver function

5. Uncontrolled thyroid disease

6. Concurrent use of any non-insulin glucose-lowering agent.

7. Hemophilia or any other bleeding disorder.

3. History of diabetic ketoacidosis (DKA) in the 6 months prior to enrollment

4. Severe hypoglycemia resulting in seizure or loss of consciousness in the 6 months prior to enrollment

5. Pregnancy or intent to become pregnant during the trial

6. Currently being treated for a seizure disorder

7. Planned surgery during study duration

8. Treatment with any non-insulin glucose-lowering agent (including metformin, GLP-1 agonists, pramlintide, DPP-4 inhibitors, SGLT-2 inhibitors, biguanides, sulfonylureas and naturaceuticals)

9. A known medical condition that in the judgment of the investigator might interfere with the completion of the protocol

10. Use of an insulin delivery mechanism that is not downloadable by the subject or study team

11. (Randomized substudy only) Current use of an automated insulin delivery system (besides LGS and PLGS) such as Medtronic 670G, Control-IQ or DIY system (or unwillingness to discontinue automated insulin delivery for three months before enrollment and the duration of the trial).

12. Having a family member(s) employed by Tandem Diabetes Care, Inc. or Dexcom, Inc.

13. Current enrollment in another clinical trial, unless approved by the investigator of both studies or if clinical trial is a non-interventional registry trial.

• Minimum Eligible Age: 11 Years
• Maximum Eligible Age: 12 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NIH

Sponsor Role: collaborator

DexCom, Inc.

INDUSTRY

Sponsor Role: collaborator

Tandem Diabetes Care, Inc.

INDUSTRY

Sponsor Role: collaborator

University of Virginia

OTHER

Sponsor Role: lead

Responsible Party

Mark D. DeBoer, MD, MSc., MCR

Professor

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Mark D. DeBoer, MD, MSc, MCR

Role: PRINCIPAL_INVESTIGATOR

UVA Center for Diabetes Technology

Locations

University of Virginia Center for Diabetes Technology

Charlottesville, Virginia, United States

Countries

United States

Provided Documents

Document Type: Informed Consent Form

View Document

Other Identifiers

1R01DK124886-01

Identifier Type: NIH

Identifier Source: secondary_id

View Link

190088

Identifier Type: -

Identifier Source: org_study_id